prikaz prve stranice dokumenta Pretransplantation monitoring of HLA antibodies by complement dependent cytotoxicity and Luminex-based assays
Rad je dostupan svim korisnicima iz sustava znanosti i visokog obrazovanja RH
Znanstveni rad - Izvorni znanstveni rad
Pretransplantation monitoring of HLA antibodies by complement dependent cytotoxicity and Luminex-based assays
Wiener klinische Wochenschrift, 129 (2017), 1/2; 33-37. https://doi.org/10.1007/s00508-016-1094-6
Katalinić, Nataša; Fućak, Marina; Crnić, Tajana; Ćurković, Milena; Starčević, Alma; Balen, Sanja

Citirajte ovaj rad

Katalinić, N., Fućak, M., Crnić, T., Ćurković, M., Starčević, A. i Balen, S. (2017). Pretransplantation monitoring of HLA antibodies by complement dependent cytotoxicity and Luminex-based assays. Wiener klinische Wochenschrift, 129. (1/2), 33-37. doi: 10.1007/s00508-016-1094-6

Katalinić, Nataša, et al. "Pretransplantation monitoring of HLA antibodies by complement dependent cytotoxicity and Luminex-based assays." Wiener klinische Wochenschrift, vol. 129, br. 1/2, 2017, str. 33-37. https://doi.org/10.1007/s00508-016-1094-6

Katalinić, Nataša, Marina Fućak, Tajana Crnić, Milena Ćurković, Alma Starčević i Sanja Balen. "Pretransplantation monitoring of HLA antibodies by complement dependent cytotoxicity and Luminex-based assays." Wiener klinische Wochenschrift 129, br. 1/2 (2017): 33-37. https://doi.org/10.1007/s00508-016-1094-6

Katalinić, N., et al. (2017) 'Pretransplantation monitoring of HLA antibodies by complement dependent cytotoxicity and Luminex-based assays', Wiener klinische Wochenschrift, 129(1/2), str. 33-37. doi: 10.1007/s00508-016-1094-6

Katalinić N, Fućak M, Crnić T, Ćurković M, Starčević A, Balen S. Pretransplantation monitoring of HLA antibodies by complement dependent cytotoxicity and Luminex-based assays. Wiener klinische Wochenschrift [Internet]. 2017. [pristupljeno 15.11.2024.];129(1/2):33-37. doi: 10.1007/s00508-016-1094-6

N. Katalinić, M. Fućak, T. Crnić, M. Ćurković, A. Starčević i S. Balen, "Pretransplantation monitoring of HLA antibodies by complement dependent cytotoxicity and Luminex-based assays", Wiener klinische Wochenschrift, vol. 129, br. 1/2, str. 33-37, 2017. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:768436. [Citirano: 15.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:768436
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Pretransplantation monitoring of HLA antibodies by complement dependent cytotoxicity and Luminex-based assays
AutorNataša Katalinić
AutorMarina Fućak
AutorTajana Crnić
AutorMilena Ćurković
AutorAlma Starčević
AutorSanja Balen
MBZ: 236875
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za kliničko-laboratorijsku dijagnostiku)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
The introduction of more sensitive techniques, such as Luminex® for HLA antibody screening of patients awaiting organ transplantation has resulted in a better understanding of transplantation immunology and improvements in clinical practice. The interpretation of the results obtained only by Luminex® can lead to inaccurate evaluation of a patient’s antibody status and unjustified rejection of a potential organ donor. The aim of this study was to demonstrate the benefits of performing HLA antibody screening in the sera of patients on the waiting list for organ transplantation by two different assays, complement dependent cytotoxicity (CDC) and Luminex®. A retrospective analysis was performed on 563 pretransplant serum samples from 141 patients on the kidney transplantation waiting list in Rijeka, tested from March 2012 until March 2015. All samples were tested in parallel by the CDC assay and the Luminex®-based assay. Out of the 563 samples tested 302 (53.7%) tested negative for HLA antibodies and 88 (15.6%) positive by both assays. From 173 (30.7%) samples with discordant results 149 (26.5%) were CDC negative and Luminex® positive, while 24 (4.3%) were CDC positive and Luminex® negative. Among the Luminex positive patients seven did not experience any immunizing events. Evaluation of the HLA antibody status in patients on a waiting list for organ transplantation should be based on the results of the both CDC and Luminex® (or other sensitive) assays in accordance to information about patient’s clinical status and exposure to immunizing events.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaWiener klinische Wochenschrift
Brojčani podacivol. 129, br. 1/2, str. 33-37
p-ISSN0043-5325
DOIhttps://doi.org/10.1007/s00508-016-1094-6
URN:NBNurn:nbn:hr:184:768436
Datum objave publikacije2017
URL dokumentahttp://bib.irb.hr/861875
Vrsta resursaTekst
Prava pristupaOgraničen pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2022-03-03 17:21:05